Nitric oxide (NO) is a potent and multifaceted bioregulatory agent. This project is aimed at a) finding ways to target NO to specific sites in the body for important research and/or therapeutic applications and b) characterizing the possible role of NO as a determinant of cancer risk. Our focus during the past year has been on elucidating the fundamental chemistry of the NO-releasing diazeniumdiolates (compounds containing the [N(O)NO] functional group) with an eye toward using our accumulating knowledge in this area to solve important research and clinical problems. Specifically, we are using the knowledge gained in our basic research investigations into the structure, spectra, dissociation to NO, alkylation, arylation, and photodegradation of the diazeniumdiolate functional group to design prodrugs that are stable at physiological pH but that can be activated to generate NO by enzymatic action. An example developed during the current reporting period is AcOM-PYRRO/NO, an esterase-sensitive diazeniumdiolate that penetrates the cell and generates NO within the cytoplasm on esterase-induced hydrolysis; AcOM-PYRRO/NO proved to be more than two orders of magnitude more potent as an inducer of apoptosis in HL-60 leukemia cells in culture than the spontaneously dissociating parent ion, PYRRO/NO. A second achievement has been the design of agents that can be activated for NO release by enzymes of the glutathione S-transferase (GST) family. The pi isoform of GST is overexpressed in some tumor cells, rendering them resistant to several lines of anticancer therapy, while the alpha isoform is vital to proper cell function. By exploiting the growing knowledge about the structures of the GSTs active sites, we have gone from an initial drug candidate whose alpha:pi rate ratio was 100 to a third generation analogue with a ratio of 0.3. If enough additional selectivity can be designed into this series, a drug capable of irreversibly inhibiting the pi enzyme while sparing the alpha may be forthcoming.We will place particular emphasis during the coming year on designing additional drugs and devices capable of targeting NO release to selected tissues for use as research tools and for possible therapeutic benefit. - Carcinogenesis, Mutagenesis, Nitric oxide, Pharmacology, Toxicology,

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Intramural Research (Z01)
Project #
1Z01BC005673-09
Application #
6289140
Study Section
Special Emphasis Panel (LCC)
Project Start
Project End
Budget Start
Budget End
Support Year
9
Fiscal Year
1999
Total Cost
Indirect Cost
Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Kogias, Evangelos; Osterberg, Nadja; Baumer, Brunhilde et al. (2012) Growth-inhibitory and chemosensitizing effects of the glutathione-S-transferase-?-activated nitric oxide donor PABA/NO in malignant gliomas. Int J Cancer 130:1184-94
Hong, Sam Y; Borchert, Gregory L; Maciag, Anna E et al. (2010) The Nitric Oxide Prodrug V-PROLI/NO Inhibits Cellular Uptake of Proline. ACS Med Chem Lett 1:386-389
Andrei, Daniela; Maciag, Anna E; Chakrapani, Harinath et al. (2008) Aryl bis(diazeniumdiolates): potent inducers of S-glutathionylation of cellular proteins and their in vitro antiproliferative activities. J Med Chem 51:7944-52
Qu, Wei; Liu, Jie; Fuquay, Richard et al. (2007) The nitric oxide prodrug, V-PYRRO/NO, mitigates arsenic-induced liver cell toxicity and apoptosis. Cancer Lett 256:238-45
Saavedra, Joseph E; Srinivasan, Aloka; Buzard, Gregory S et al. (2006) PABA/NO as an anticancer lead: analogue synthesis, structure revision, solution chemistry, reactivity toward glutathione, and in vitro activity. J Med Chem 49:1157-64
Reynolds, Melissa M; Hrabie, Joseph A; Oh, Bong K et al. (2006) Nitric oxide releasing polyurethanes with covalently linked diazeniumdiolated secondary amines. Biomacromolecules 7:987-94
Inami, Keiko; Nims, Raymond W; Srinivasan, Aloka et al. (2006) Metabolism of a liver-selective nitric oxide-releasing agent, V-PYRRO/NO, by human microsomal cytochromes P450. Nitric Oxide 14:309-15
Shami, Paul J; Saavedra, Joseph E; Bonifant, Challice L et al. (2006) Antitumor activity of JS-K [O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate] and related O2-aryl diazeniumdiolates in vitro and in vivo. J Med Chem 49:4356-66
Townsend, Danyelle M; Findlay, Victoria J; Fazilev, Farit et al. (2006) A glutathione S-transferase pi-activated prodrug causes kinase activation concurrent with S-glutathionylation of proteins. Mol Pharmacol 69:501-8
Waterhouse, David J; Saavedra, Joseph E; Davies, Keith M et al. (2006) Injectable formulation of disodium 1-[2-(carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolate (PROLI/NO), an ultrafast nitric oxide donor prodrug. J Pharm Sci 95:108-15

Showing the most recent 10 out of 28 publications